Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
14.18
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
14.18
Bid (Size)
5.680 (2)
Ask (Size)
22.54 (1)
Prev. Close
14.18
Today's Range
14.18 - 14.18
52wk Range
9.900 - 17.73
Shares Outstanding
58,041,410
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 09, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
-14.32%
-14.32%
1 Month
-4.32%
-4.32%
3 Month
-1.18%
-1.18%
6 Month
+39.29%
+39.29%
1 Year
-1.46%
-1.46%
More News
Read More
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
February 06, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For February 6, 2024
February 06, 2024
Via
Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
February 05, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
November 20, 2023
Via
Benzinga
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 18, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
January 08, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
January 05, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
November 07, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
October 30, 2023
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
August 21, 2023
Via
InvestorPlace
3 Under-the-Radar Biotech Stocks to Buy in 2023
August 19, 2023
Via
The Motley Fool
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Why Shares of Deciphera Pharmaceuticals Rose This Week
August 11, 2023
Via
The Motley Fool
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
August 10, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.